Matthew Genyeh Mei, M.D.

800-826-4839
Matthew Genyeh Mei, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Hodgkin Lymphoma
  • Non-Hodgkin Lymphoma
  • Cellular Immunotherapy
  • Autologous Stem Cell Transplantation
  • Allogeneic Stem Cell Transplantation
  • Scleroderma
  • Germ Cell Tumors
Research Area
  • Hematology and Hematopoietic Cell Transplantation
  • Lymphoma
Other Languages Spoken
Mandarin
Spanish
Academic Appointments
  • Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation
  • Program Director, Hematology and Medical Oncology Fellowship Program
Clinical Teams
Lymphoma
Hematology & Hematopoietic Cell Transplantation
Research Teams
Lymphoma Research

Matthew G. Mei, M.D., is an associate professor in the Department of Hematology & Hematopoietic Cell Transplantation who specializes in the treatment of lymphomas as well as stem cell transplantation and cellular immunotherapy. He earned his medical degree at Case Western Reserve University in Cleveland and completed his residency at University of California San Francisco. He completed a fellowship in hematology/oncology at City of Hope in 2014 and joined the hematology faculty that year. He is an active clinical researcher and has led multiple clinical trials in the areas of lymphoma, stem cell transplant, and immunotherapy. He is also heavily invested in medical education and is the program director for the ACGME hematology/oncology fellowship.

Location

Education & Experience

Board Certifications

  • 2014, Hematology

  • 2014, Medical Oncology

  • 2010, Board Certification, American Board of Internal Medicine

  • 2009, Drug Enforcement Agency Certificate

Degrees

  • 2007, M.D., Case Western Reserve University, Cleveland, OH

  • 2003, A.B. magna cum laude, biochemical sciences, Harvard University, Cambridge, MA

Fellowship

  • 2011-2014, Fellow, Hematology and Medical Oncology, Harbor-UCLA / City of Hope, Los Angeles, CA

Residency

  • 2007-2010, Internal medicine resident, University of California San Francisco, San Francisco, CA

Professional Experience

  • 2023-present, Program Director, Hematology and Medical Oncology Fellowship

  • 2020-present, Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2014-2020, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

  • 2011-2014, On-call medicine physician, City of Hope, Duarte, CA

  • 2010-2011, Oncology hospitalist, University of California San Francisco, San Francisco, CA

Awards & Memberships

Awards

  • 2018, Leukemia Research Foundation New Investigator Award

  • 2012, Ariad Travel Fellowship

  • 2004, American Federation for Aging Research Geriatrics Grant

  • 2002, Harvard College Research Program

  • 2001-2002, John Harvard Scholar

Publications

  • Godfrey J, Mei M, Chen L, Song JY, Bedell V, Budde E, Armenian S, Puverel S, Nikolaenko L, Chen R, Daniels S, Kennedy N, Peters L, Rosen ST, Forman SJ, Popplewell LL, Kwak LW, Herrera AF. Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma. Haematologica. 2023 Jul 20. doi: 10.3324/haematol.2023.283002. Epub ahead of print.
  • Epperla N, Kumar A, Abutalib SA, Awan FT, Chen YB, Gopal AK, Holter-Chakrabarty J, Kekre N, Lee CJ, Lekakis L, Lin Y, Mei M, Nathan S, Nastoupil L, Oluwole O, Phillips AA, Reid E, Rezvani AR, Trotman J, Zurko J, Kharfan-Dabaja MA, Sauter CS, Perales MA, Locke FL, Carpenter PA, Hamadani M. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther. 2023 Jul 5:S2666-6367(23)01361-1. doi: 10.1016/j.jtct.2023.06.012. Epub ahead of print.
  • Mei M, Chen L, Godfrey J, Song JY, Egelston C, Budde LE, Armenian SH, Nikolaenko L, Nwangwu M, Guo W, Gao L, Lee P, Chen RW, Daniels S, Kennedy N, Peters L, Zain J, Rosen ST, Forman SJ, Popplewell L, Kwak LW, Herrera AF. Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade. Blood. 2023 Jun 20:blood.2023020485. doi: 10.1182/blood.2023020485. Epub ahead of print.
  • Rainone M, Kasparian S, Nguyen T, Talwar N, Yuan Y, Mei M, Mortimer JE, Waisman JR, Patel N, Pullarkat V. Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates. Oncologist. 2023 Jun 19:oyad185. doi: 10.1093/oncolo/oyad185. Epub ahead of print.
  • Mei M, Palmer J, Tsai NN, Simpson J, O'Hearn J, Stein A, Forman S, Spielberger R, Cai JL, Htut M, Nakamura R, Al Malki MM, Herrera A, Wong J, Nademanee A. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Clin Lymphoma Myeloma Leuk. 2023 May 23:S2152-2650(23)00169-6.
  • Mei M, Herrera AF. The next frontier: enter PD-1 and exit PET scans? Blood. 2023 May 25;141(21):2545-2546.
  • Mei M, Herrera AF. Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant? Haematologica. 2023 Apr 6. doi: 10.3324/haematol.2023.282731. Epub ahead of print. PMID: 37021531.
  • Lee K, Iukuridze A, He T, Bosworth A, Lindenfeld L, Teh JB, Echevarria M, Albanese S, Atencio L, Bhandari R, Wong FL, Artz AS, Siddiqi T, Nikolaenko L, Zain J, Mei M, Shouse G, Popplewell LL, Herrera AF, Budde LE, Forman SJ, Armenian SH. Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy. J Natl Compr Canc Netw. 2023 Apr;21(4):373-382.e1. doi: 10.6004/jnccn.2022.7100. PMID: 37015335.
  • Ladbury C, Dandapani S, Hao C, Fabros M, Amini A, Sampath S, Glaser S, Sokolov K, Yeh J, Baird JH, Kambhampati S, Herrera A, Mei M, Nikolaenko L, Shouse G, Budde LE. Long-Term Follow-Up of Bridging Therapies Prior to CAR T-Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma. Cancers (Basel). 2023 Mar 14;15(6):1747. doi: 10.3390/cancers15061747. PMID: 36980632; PMCID: PMC10046245.
  • Mei M, Perini G, Ramchandren R. Editorial: Advances in the treatment of Hodgkin lymphoma. Front Oncol. 2023 Feb 28;13:1164081.
  • Ladbury C, Mei M, Kafaja S, Nall J, Han C, Dandapani S, Forman S, Wong JYC. Autologous Stem Cell Transplantation with Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis. Int J Radiat Oncol Biol Phys. 2023 Mar 1:S0360-3016(23)00200-6. doi: 10.1016/j.ijrobp.2023.02.042. Epub ahead of print. PMID: 36868524.
  • Mei M, Masucci L, Jain MD. Cellular therapy: Great promise, but at what cost? Mol Ther. 2023 Jan 4;31(1):5-6. doi: 10.1016/j.ymthe.2022.11.010. Epub 2022 Nov 30. PMID: 36455550; PMCID: PMC9840137.
  • Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e14-e23. doi: 10.1016/S2352-3026(22)00318-0. Epub 2022 Nov 17. PMID: 36403579.
  • Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei M, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 Jan 1;108(1):98-109. doi: 10.3324/haematol.2022.281242. PMID: 35833303; PMCID: PMC9827150.
  • Kambhampati S, Saumoy M, Schneider Y, Pak S, Budde LE, Mei M, Siddiqi T, Popplewell LL, Wen YP, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. Blood. 2022 Dec 22;140(25):2697-2708. doi: 10.1182/blood.2022016624. PMID: 35700381.
  • Kambhampati S, Saumoy M, Schneider Y, Serrao S, Solaimani P, Budde LE, Mei M, Popplewell LL, Siddiqi T, Zain J, Forman SJ, Kwak LW, Rosen ST, Danilov AV, Herrera AF, Thiruvengadam NR. Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma. Blood. 2022 Nov 10;140(19):2024-2036. doi: 10.1182/blood.2022016747. PMID: 35914220; PMCID: PMC9837443.
  • Kambhampati S, Mei M, Godfrey J, Siddiqi T, Salhotra A, Chen R, Smith E, Popplewell LL, Herrera AF. PD-1 Blockade After Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2022 Oct;22(10):e893-e897. doi: 10.1016/j.clml.2022.06.004. Epub 2022 Jun 6. PMID: 35778267.
  • Aldoss I, Yang D, Tomasian V, Mokhtari S, Jackson R, Gu Z, Telatar M, Yew H, Al Malki MM, Salhotra A, Khaled S, Ali H, Aribi A, Sandhu KS, Mei M, Arslan S, Koller P, Artz A, Aoun P, Gu D, Snyder D, Stewart FM, Curtin P, Stein AS, Pillai R, Marcucci G, Forman SJ, Pullarkat V, Nakamura R, Afkhami M. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL. Blood Adv. 2022 Sep 13;6(17):4936-4948. doi: 10.1182/bloodadvances.2022007597. PMID: 35816633; PMCID: PMC9631622.
  • Mei M, Pillai R, Kim S, Estrada-Merly N, Afkhami M, Yang L, Meng Z, Abid MB, Aljurf M, Bacher U, Beitinjaneh A, Bredeson C, Cahn JY, Cerny J, Copelan E, Cutler C, DeFilipp Z, Diaz Perez MA, Farhadfar N, Freytes CO, Gadalla SM, Ganguly S, Gale RP, Gergis U, Grunwald MR, Hamilton BK, Hashmi S, Hildebrandt GC, Lazarus HM, Litzow M, Munker R, Murthy HS, Nathan S, Nishihori T, Patel SS, Rizzieri D, Seo S, Shah MV, Solh M, Verdonck LF, Vij R, Sobecks RM, Oran B, Scott BL, Saber W, Nakamura R. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2022 Apr 21.
  • Mei M, Lee HJ, Palmer J, Chen RW, Tsai NC, Chen L, McBride K, Smith DL, Melgar I, Song JY, Bonjoc KC, Armenian S, Nwangwu M, Lee P, Zain J, Nikolaenko L, Popplewell L, Nademanee A, Chaudhry AA, Rosen ST, Kwak LW, Forman SJ, Herrera AF. Response-adapted anti-PD1 based salvage therapy for Hodgkin lymphoma with nivolumab +/- ICE (NICE). Blood. 2022 Mar 22: blood.2022015423.
  • Ali H, Tsai NC, Synold T, Mokhtari S, Tsia W, Palmer J, Stiller T, Al Malki M, Aldoss I, Salhotra A, Rahmanuddin S, Pullarkat V, Cai JL, Stein A, Forman SJ, Marcucci G, Mei M, Snyder DS, Nakamura R. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study. Blood Adv. 2022 Mar 8;6(5):1444-1453.
  • Arslan S, Ali H, Mei M, Marcucci G, Forman S, Nakamura R, Stein A, Al Malki MM. Successful treatment of refractory pure red cell aplasia in major ABO-mismatched allogeneic hematopoietic stem cell transplant with single agent Ibrutinib. Bone Marrow Transplant. 2022 May;57(5):830-833. doi: 10.1038/s41409-022-01590-0. Epub 2022 Feb 22. PMID: 35194155.
  • Mei M, Hamadani M, Ahn KW, Chen Y, Kharfan-Dabaja MA, Sauter C, Herrera AF. Autologous hematopoietic cell transplantation in diffuse large B-cell lymphoma after 3 or more lines of prior therapy: evidence of durable benefit. Haematologica. 2022 Feb 3.
  • Ladbury C, Kambhampati S, Othman T, Hao C, Chen L, Wong J, Cao T, Herrera A, Mei M, Dandapani S. Role of Salvage Radiation Treatment of Relapses in Relapsed/Refractory Diffuse Large B Cell Lymphoma Post Autologous Stem Cell Transplant. Int J Radiat Oncol Biol Phys. 2022 Feb 14:S0360-3016(22)00161-4.
  • Herrera AF, Palmer J, Adhikarla V, Yamauchi D, Poku EK, Bading J, Yazaki P, Dandapani S, Mei M, Chen R, Cao T, Karras N, McTague P, Nademanee A, Popplewell L, Sahebi F, Shively JE, Simpson J, Smith DL, Song J, Spielberger R, Tsai NC, Thomas SH, Forman SJ, Colcher D, Wu AM, Wong J, Smith E. Anti-CD25 radioimmunotherapy with BEAM autologous hematopoietic cell transplantation conditioning in Hodgkin lymphoma. Blood Adv. 2021 Dec 14;5(23):5300-5311.
  • Aldoss I, Pillai R, Yang D, Yang L, Arslan S, Mokhtari S, Malki MMA, Salhotra A, Shahani S, Ali H, Mei M, Artz A, Snyder D, Afkhami M, Armenian S, Stein A, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Late and very late relapsed acute lymphoblastic leukemia: clinical and molecular features, and treatment outcomes. Blood Cancer J. 2021 Jul 2;11(7):125.
  • Gordon MJ, Kaempf A, Sitlinger A, Shouse G, Mei M, Brander DM, Salous T, Hill BT, Alqahtani H, Choi M, Churnetski MC, Cohen JB, Stephens DM, Siddiqi T, Rivera X, Persky D, Wisniewski P, Patel K, Shadman M, Park B, Danilov AV. The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clin Cancer Res. 2021 Sep 1;27(17):4814-4824.
  • Aldoss I, Yang D, Malki MMA, Mei M, Mokhtari S, Artz A, Cao T, Salhotra A, Ali H, Aribi A, Khaled S, Arslan S, Sandhu K, Koller P, Mansour J, Spielberger R, Stein A, Snyder D, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies. Transplant Cell Ther. 2021 Mar;27(3):255.e1-255.e9.
  • Amanam I, Gupta R, Pullarkat V, Mei M. Immune thrombocytopenia after immune checkpoint inhibitor therapy. Br J Haematol. 2021 May;193(3):677-681.
  • Othman TA, Mei M, Zhang J, Aldoss I, Stein A, Forman SJ, Marcucci G, Pullarkat V. Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents. 2021 May 1;96(5):E140-E143.
  • Ansell SM, Maris M, Lesokhin AM, Chen R, Flinn IW, Sawas A, Minden MD, Villa D, Percival MM, Advani AS, Foran JM, Horwitz S, Mei M, Zain J, Savage KJ, Querfeld C, Akilov OE, Johnson LD, Catalano T, Petrova PS, Uger RA, Sievers EL, Milea A, Roberge K, Shou Y, O'Connor OA. Phase 1 Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies. 2021 Apr 15;27(8):2190-2199.
  • Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-Marketing Analysis. Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):170-175.
  • Sandhu KS, Dadwal S, Yang D, Mei M, Palmer J, Salhotra A, Al Malki M, Aribi A, Ali H, Khaled S, Forman SJ, Snyder D, Nakamura R, Stein AS, Marcucci G, Aldoss I, Pullarkat V. Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2020 Dec;26(12):e322-e327.
  • Othman TA, Zhang J, Mei M, Stein AS, Forman SJ, Marcucci G, Pullarkat V, Aldoss I. Leuk Lymphoma. Retreatment with venetoclax and hypomethylating agents among AML patients who have relapsed after initial response and subsequent interruption of therapy. 2020 Dec;61(14):3532-3533.
  • Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 Sep 20;38(27):3095-3106.
  • Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AA, Marcucci G, Pullarkat V. Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Am J Hematol. 2020 Jul 6.
  • Mei M, Tsai NC, Mokhtari S, Malki MMA, Ali H, Salhotra A, Sandhu K, Khaled S, Smith E, Snyder D, Marcucci G, Forman SJ, Pullarkat V, Stein A, Aldoss I, Nakamura R. Long-term Outcomes of Allogeneic Hematopoietic Cell transplantation with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as GVHD prophylaxis in Patients with Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2020 Aug;26(8):1425-1432.
  • Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, Fenske TS, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 Aug;190(4):573-582.
  • Gupta R, Othman T, Uche A, Amanam I, Chen C, Celles L, Lane G, Mei M, Aldoss I, Pullarkat V, Kim P, Yeh J. Characteristics and Trends of Adult Acute Lymphoblastic Leukemia in a Large, Public Safety-Net Hospital. Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):e320-e327.
  • Jagadeesh D, Majhail NS, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan Geethakumari P, Savani BN, Yared JA, Fenske TS, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of Rituximab-BEAM Versus BEAM Conditioning Regimen in Patients With Diffuse Large B Cell Lymphoma Undergoing Autologous Transplantation. Cancer. 2020 May 15;126(10):2279-2287.
  • Salhotra A, Yang D, Mokhtari S, Malki MMA, Ali H, Sandhu KS, Aribi A, Khaled S, Mei M, Budde E, Snyder D, Cao T, Spielberger R, Marcucci G, Pullarkat V, Forman SJ, Nakamura R, Stein A, Aldoss I. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia. Biol Blood Marrow Transplant. 2020 Jun;26(6):1084-1090.
  • Salhotra A, Hui S, Yang D, Mokhtari S, Mei M, Al Malki MM, Aldoss I, Ali H, Sandhu KS, Aribi A, Khaled S, Dandapani S, Peng K, Teh JB, Murata-Collins J, Budde E, Dadwal S, Pullarkat V, Snyder D, Spielberger R, Wong J, Armenian S, Marcucci G, Forman SJ, Nakamura R, Stein A. Long term outcomes of patients with Acute Myeloid Leukemia treated with myeloablative FTBI based conditioning with Tacrolimus and sirolimus based GVHD prophylaxis regimen: 6 year follow up from Single Center. Biol Blood Marrow Transplant. 2020 Feb;26(2):292-299.
  • Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019 Dec 10;3(23):4043-4049.
  • Chen R, Herrera AF, Hou J, Chen L, Wu J, Guo Y, Synold TW, Ngo VN, Puverel S, Mei M, Popplewell L, Yi S, Song JY, Tao S, Wu X, Chan WC, Forman S, Kwak LW, Rosen ST, Newman EM. Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma. Clin Cancer Res. 2020 Mar 1;26(5):1034-1044.
  • Gupta R, Jamal F, Yang D, Chendri C, Aldoss I, Malki MA, Mei M, Salhotra A, Dobrin S, Tran M, Venkataraman K, Palmer J, Stein AS, Sandhu K, Khaled S, Aribi A, Marcucci G, Forman SJ, Snyder D, Nakamura R, Ali H, Pullarkat V. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis. Bone Marrow Transplant. 2020 May;55(5):877-883.
  • Slavin TP, Teh JB, Weitzel JN, Peng K, Wong FL, Qin H, Wang J, Wu X, Mei M, Pillai R, Wang Y, Tsang KK, Pozhitkov A, Krishnan A, Forman SJ, Armenian SH. Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 Dec;25(12):2517-2521.
  • Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. Br J Haematol. 2019 Oct;187(2):e45-e48.
  • Aldoss I, Yang D, Pillai R, Sanchez JF, Mei M, Aribi A, Ali H, Sandhu K, Al Malki MM, Salhotra A, Khaled S, Sun W, O'Donnell M, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia. Am J Hematol. 2019 Oct;94(10):E253-E255.
  • Salhotra A, Afkhami M, Yang D, Mokhtari S, Telatar M, Gu D, Pillai RK, Weisenburger DD, Murata-Collins J, Weigel D, Aoun P, Aldoss I, Al Malki MM, Khaled S, Mei M, Ali H, Aribi A, Budde E, Sandhu K, O'Donnell M, Snyder D, Pullarkat V, Forman SJ, Marcucci G, Nakamura R, Stein A. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations. Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e400-e405.
  • Mei M, Gupta R, O'Donnell M, Al Malki MM, Aldoss I, Ali H, Farol L, Snyder D, Forman SJ, Nakamura R, Khaled S. Post-allogeneic eculizumab as prophylaxis against hemolysis and thrombosis for patients with hematologic disorders associated with PNH clones. Biol Blood Marrow Transplant. Biol Blood Marrow Transplant. 2019 May;25(5):e183-e185.
  • Salhotra A, Mei M, Stiller T, Mokhtari S, Herrera AF, Chen R, Popplewell L, Zain J, Ali H, Sandhu K, Budde E, Nademanee A, Forman SJ, Nakamura R. Outcomes of patients with recurrent and refractory lymphoma undergoing allogeneic hematopoietic cell transplantation with BEAM conditioning and sirolimus and tacrolimus based GVHD prophylaxis. Biol Blood Marrow Transplant. 2019 Feb;25(2):287-292.
  • Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, Mei M, Popplewell L, Pham LV, Kwak LW, Weisenburger DD, Rosen ST, Chan WC, Müschen M, Ngo VN. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. Blood. 2019 Jan 24;133(4):306-318.
  • Ali H, Aldoss I, Yang D, Mokhtari S, Khaled S, Aribi A, Afkhami M, Al Malki MM, Cao T, Mei M, O'Donnell M, Salhotra A, Pullarkat V, Yang L, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pillai R, Snyder D. MIPSS70+ v2.0 predicts long-term survival in myelofibrosis after allogeneic HCT with the Flu/Mel conditioning regimen. Blood Adv. 2019 Jan 8;3(1):83-95.
  • Padeganeh A, Song J, Aoun P, Mei M, Ali H, Weisenburger DD, Murata-Collins JL. Clinical Relevance of Normal Diploid Workflow in Microarray Analysis of Massively Aneuploid Genomes: Lessons from a Case of B-Lymphoblastic Leukemia. Atlas Genet Cytogenet Oncol Haematol. in press.

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Provider listen carefully to you
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
06/16/24
All terrific - Verified patient
04/30/24
Very good - Verified patient
03/23/24
City of Hope is like a well oiled machine - so organized and helpful. It was actually comforting - Verified patient
03/23/24
Dr. Mei is a rock star! - Verified patient
03/08/24
Dr. Mei completely assuaged our fears, answered our questions and explained our future care. - Verified patient